Merck Q2 sales $11.4B (+22% YoY); raises full-year revenue guidance to $46.4B-$47.4B

Merck & Co., Inc.

2021-Q2 EPS reported $1.86 revenue$22,029,000,000

GAAP EPS $0.48; non-GAAP EPS $1.31, up 28% YoY on strong demand recovery.
KEYTRUDA sales $4.2B (+23%); GARDASIL $1.2B (+88%) driven by pandemic recovery.
Completed Organon spinoff on June 2; received ~$9B cash distribution.
Full-year non-GAAP EPS guidance raised to $5.47-$5.57, including ~2% FX benefit.
FDA approvals for VAXNEUVANCE, KEYTRUDA in TNBC and endometrial carcinoma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.